海外の治験の状況「1」での検索結果
2290件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Recruiting
- Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
- Advanced Malignant Solid Neoplasm;Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;Deleterious ATM Gene Mutation;Deleterious BRCA1 Gene Mutation;Deleterious BRCA2 Gene Mutation;Deleterious RAD51C Gene Mutation;Deleterious RAD51D Gene Mutation;Histiocytosis;Low Grade Glioma;Malignant Glioma;Recurrent Childhood Central Nervous System Neoplasm;Recurrent Childhood Ependymoma;Recurrent Childhood Malignant Germ Cell Tumor;Recurrent Childhood Non-Hodgkin Lymphoma;Recurrent Childhood Rhabdomyosarcoma;Recurrent Childhood Soft Tissue Sarcoma;Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;Recurrent Glioma;Recurrent Hepatoblastoma;Recurrent Langerhans Cell Histiocytosis;Recurrent Malignant Solid Neoplasm;Recurrent Medulloblastoma;Recurrent Neuroblastoma;Recurrent Osteosarcoma;Refractory Central Nervous System Neoplasm;Refractory Langerhans Cell Histiocytosis;Refractory Malignant Solid Neoplasm;Refractory Neuroblastoma;Refractory Non-Hodgkin Lymphoma;Rhabdoid Tumor;Wilms Tumor
- Puerto Rico, United States
- 2017-07-25
Recruiting
- PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
- Advanced Malignant Solid Neoplasm;Ann Arbor Stage III Non-Hodgkin Lymphoma;Ann Arbor Stage IV Non-Hodgkin Lymphoma;Malignant Glioma;Recurrent Central Nervous System Neoplasm;Recurrent Childhood Ependymoma;Recurrent Ewing Sarcoma;Recurrent Glioma;Recurrent Hepatoblastoma;Recurrent Langerhans Cell Histiocytosis;Recurrent Malignant Germ Cell Tumor;Recurrent Malignant Solid Neoplasm;Recurrent Medulloblastoma;Recurrent Neuroblastoma;Recurrent Non-Hodgkin Lymphoma;Recurrent Osteosarcoma;Recurrent Peripheral Primitive Neuroectodermal Tumor;Recurrent Rhabdomyosarcoma;Recurrent Soft Tissue Sarcoma;Refractory Central Nervous System Neoplasm;Refractory Langerhans Cell Histiocytosis;Refractory Malignant Germ Cell Tumor;Refractory Malignant Solid Neoplasm;Refractory Neuroblastoma;Refractory Non-Hodgkin Lymphoma;Rhabdoid Tumor;Stage III Osteosarcoma AJCC v7;Stage III Soft Tissue Sarcoma AJCC v7;Stage IV Osteosarcoma AJCC v7;Stage IV Soft Tissue Sarcoma AJCC v7;Stage IVA Osteosarcoma AJCC v7;Stage IVB Osteosarcoma AJCC v7;TSC1 Gene Mutation;TSC2 Gene Mutation;Wilms Tumor
- Puerto Rico, United States
- 2017-07-10
Recruiting
- Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
- Advanced Malignant Solid Neoplasm;Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;Malignant Glioma;NTRK1 Fusion Positive;NTRK2 Fusion Positive;NTRK3 Fusion Positive;Recurrent Central Nervous System Neoplasm;Recurrent Childhood Ependymoma;Recurrent Childhood Malignant Germ Cell Tumor;Recurrent Childhood Medulloblastoma;Recurrent Childhood Non-Hodgkin Lymphoma;Recurrent Childhood Rhabdomyosarcoma;Recurrent Childhood Soft Tissue Sarcoma;Recurrent Ewing Sarcoma;Recurrent Glioma;Recurrent Hepatoblastoma;Recurrent Langerhans Cell Histiocytosis;Recurrent Malignant Solid Neoplasm;Recurrent Neuroblastoma;Recurrent Osteosarcoma;Recurrent Peripheral Primitive Neuroectodermal Tumor;Refractory Central Nervous System Neoplasm;Refractory Childhood Malignant Germ Cell Tumor;Refractory Langerhans Cell Histiocytosis;Refractory Malignant Solid Neoplasm;Refractory Neuroblastoma;Refractory Non-Hodgkin Lymphoma;Rhabdoid Tumor;Stage III Osteosarcoma AJCC v7;Stage III Soft Tissue Sarcoma AJCC v7;Stage IV Osteosarcoma AJCC v7;Stage IV Soft Tissue Sarcoma AJCC v7;Stage IVA Osteosarcoma AJCC v7;Stage IVB Osteosarcoma AJCC v7;Wilms Tumor
- Puerto Rico, United States
- 2017-07-10
Recruiting
- Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
- Acinar Cell Carcinoma;Adenoid Cystic Carcinoma;Adrenal Cortex Carcinoma;Adrenal Gland Pheochromocytoma;Anal Canal Neuroendocrine Carcinoma;Anal Canal Undifferentiated Carcinoma;Appendix Mucinous Adenocarcinoma;Bartholin Gland Transitional Cell Carcinoma;Bladder Adenocarcinoma;Cervical Adenocarcinoma;Cholangiocarcinoma;Chordoma;Colorectal Squamous Cell Carcinoma;Desmoid-Type Fibromatosis;Endometrial Transitional Cell Carcinoma;Endometrioid Adenocarcinoma;Esophageal Neuroendocrine Carcinoma;Esophageal Undifferentiated Carcinoma;Extrahepatic Bile Duct Carcinoma;Fallopian Tube Adenocarcinoma;Fallopian Tube Transitional Cell Carcinoma;Fibromyxoid Tumor;Gastric Neuroendocrine Carcinoma;Gastric Squamous Cell Carcinoma;Gastric Undifferentiated Carcinoma;Gastrointestinal Stromal Tumor;Giant Cell Carcinoma;Intestinal Neuroendocrine Carcinoma;Intrahepatic Cholangiocarcinoma;Lung Carcinoid Tumor;Lung Sarcomatoid Carcinoma;Major Salivary Gland Carcinoma;Malignant Odontogenic Neoplasm;Malignant Peripheral Nerve Sheath Tumor;Malignant Testicular Sex Cord-Stromal Tumor;Metaplastic Breast Carcinoma;Metastatic Malignant Neoplasm of Unknown Primary Origin;Minimally Invasive Lung Adenocarcinoma;Mixed Mesodermal (Mullerian) Tumor;Mucinous Adenocarcinoma;Mucinous Cystadenocarcinoma;Nasal Cavity Adenocarcinoma;Nasal Cavity Carcinoma;Nasopharyngeal Carcinoma;Nasopharyngeal Papillary Adenocarcinoma;Nasopharyngeal Undifferentiated Carcinoma;Oral Cavity Carcinoma;Oropharyngeal Undifferentiated Carcinoma;Ovarian Adenocarcinoma;Ovarian Germ Cell Tumor;Ovarian Mucinous Adenocarcinoma;Ovarian Squamous Cell Carcinoma;Ovarian Transitional Cell Carcinoma;Pancreatic Acinar Cell Carcinoma;Pancreatic Neuroendocrine Carcinoma;Paraganglioma;Paranasal Sinus Adenocarcinoma;Paranasal Sinus Carcinoma;Parathyroid Gland Carcinoma;Pituitary Gland Carcinoma;Placental Choriocarcinoma;Placental-Site Gestational Trophoblastic Tumor;Primary Peritoneal High Grade Serous Adenocarcinoma;Pseudomyxoma Peritonei;Rare Disorder;Scrotal Squamous Cell Carcinoma;Seminal Vesicle Adenocarcinoma;Seminoma;Serous Cystadenocarcinoma;Small Intestinal Adenocarcinoma;Small Intestinal Squamous Cell Carcinoma;Spindle Cell Neoplasm;Squamous Cell Carcinoma of the Penis;Teratoma With Malignant Transformation;Testicular Non-Seminomatous Germ Cell Tumor;Thyroid Gland Carcinoma;Tracheal Carcinoma;Transitional Cell Carcinoma;Ureter Adenocarcinoma;Ureter Squamous Cell Carcinoma;Urethral Adenocarcinoma;Urethral Squamous Cell Carcinoma;Vaginal Adenocarcinoma;Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;Vulvar Carcinoma
- United States
- 2016-07-13
Recruiting
- Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
- Anemia;B-Cell Prolymphocytic Leukemia;Fatigue;Fever;Grade 1 Follicular Lymphoma;Grade 2 Follicular Lymphoma;Grade 3a Follicular Lymphoma;Hairy Cell Leukemia;Lymphadenopathy;Lymphocytosis;Lymphoplasmacytic Lymphoma;Mantle Cell Lymphoma;Marginal Zone Lymphoma;Night Sweats;Recurrent Chronic Lymphocytic Leukemia;Recurrent Small Lymphocytic Lymphoma;Refractory Chronic Lymphocytic Leukemia;Refractory Small Lymphocytic Lymphoma;Richter Syndrome;Splenomegaly;Thrombocytopenia;Weight Loss;Anemia;B-Cell Prolymphocytic Leukemia;Fatigue;Fever;Grade 1 Follicular Lymphoma;Grade 2 Follicular Lymphoma;Grade 3a Follicular Lymphoma;Hairy Cell Leukemia;Lymphadenopathy;Lymphocytosis;Lymphoplasmacytic Lymphoma;Mantle Cell Lymphoma;Marginal Zone Lymphoma;Night Sweats;Recurrent Chronic Lymphocytic Leukemia;Recurrent Small Lymphocytic Lymphoma;Refractory Chronic Lymphocytic Leukemia;Refractory Small Lymphocytic Lymphoma;Richter Syndrome;Splenomegaly;Thrombocytopenia;Weight Loss
- United States
- 2017-01-03
Recruiting
- Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
- Adult Grade III Lymphomatoid Granulomatosis;B-cell Chronic Lymphocytic Leukemia;Contiguous Stage II Adult Diffuse Large Cell Lymphoma;Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;Contiguous Stage II Grade 1 Follicular Lymphoma;Contiguous Stage II Grade 2 Follicular Lymphoma;Contiguous Stage II Grade 3 Follicular Lymphoma;Contiguous Stage II Mantle Cell Lymphoma;Contiguous Stage II Marginal Zone Lymphoma;Contiguous Stage II Small Lymphocytic Lymphoma;Cutaneous B-cell Non-Hodgkin Lymphoma;Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;Intraocular Lymphoma;Nodal Marginal Zone B-cell Lymphoma;Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;Noncontiguous Stage II Grade 1 Follicular Lymphoma;Noncontiguous Stage II Grade 2 Follicular Lymphoma;Noncontiguous Stage II Grade 3 Follicular Lymphoma;Noncontiguous Stage II Mantle Cell Lymphoma;Noncontiguous Stage II Marginal Zone Lymphoma;Noncontiguous Stage II Small Lymphocytic Lymphoma;Progressive Hairy Cell Leukemia, Initial Treatment;Small Intestine Lymphoma;Splenic Marginal Zone Lymphoma;Stage 0 Chronic Lymphocytic Leukemia;Stage I Adult Diffuse Large Cell Lymphoma;Stage I Adult Diffuse Mixed Cell Lymphoma;Stage I Adult Diffuse Small Cleaved Cell Lymphoma;Stage I Adult Hodgkin Lymphoma;Stage I Adult Immunoblastic Large Cell Lymphoma;Stage I Chronic Lymphocytic Leukemia;Stage I Grade 1 Follicular Lymphoma;Stage I Grade 2 Follicular Lymphoma;Stage I Grade 3 Follicular Lymphoma;Stage I Mantle Cell Lymphoma;Stage I Marginal Zone Lymphoma;Stage I Small Lymphocytic Lymphoma;Stage II Adult Hodgkin Lymphoma;Stage II Chronic Lymphocytic Leukemia;Stage II Small Lymphocytic Lymphoma;Stage III Adult Diffuse Large Cell Lymphoma;Stage III Adult Diffuse Mixed Cell Lymphoma;Stage III Adult Diffuse Small Cleaved Cell Lymphoma;Stage III Adult Hodgkin Lymphoma;Stage III Adult Immunoblastic Large Cell Lymphoma;Stage III Chronic Lymphocytic Leukemia;Stage III Grade 1 Follicular Lymphoma;Stage III Grade 2 Follicular Lymphoma;Stage III Grade 3 Follicular Lymphoma;Stage III Mantle Cell Lymphoma;Stage III Marginal Zone Lymphoma;Stage III Small Lymphocytic Lymphoma;Stage IV Adult Diffuse Large Cell Lymphoma;Stage IV Adult Diffuse Mixed Cell Lymphoma;Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;Stage IV Adult Hodgkin Lymphoma;Stage IV Adult Immunoblastic Large Cell Lymphoma;Stage IV Chronic Lymphocytic Leukemia;Stage IV Grade 1 Follicular Lymphoma;Stage IV Grade 2 Follicular Lymphoma;Stage IV Grade 3 Follicular Lymphoma;Stage IV Mantle Cell Lymphoma;Stage IV Marginal Zone Lymphoma;Stage IV Small Lymphocytic Lymphoma;Testicular Lymphoma;Untreated Hairy Cell Leukemia;Waldenström Macroglobulinemia
- United States
- 2014-08-05
Recruiting
- Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;Acute Biphenotypic Leukemia;Acute Leukemia of Ambiguous Lineage;Acute Undifferentiated Leukemia;Adult Acute Lymphoblastic Leukemia in Remission;Adult Acute Myeloid Leukemia in Remission;Allogeneic Hematopoietic Stem Cell Transplantation Recipient;Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;Blastic Plasmacytoid Dendritic Cell Neoplasm;Childhood Acute Lymphoblastic Leukemia in Remission;Childhood Acute Myeloid Leukemia in Remission;Donor;Lymphoblastic Lymphoma;Myelodysplastic Syndrome With Excess Blasts;Myelodysplastic Syndrome With Excess Blasts-1;Myelodysplastic Syndrome With Excess Blasts-2;Recurrent Adult Acute Lymphoblastic Leukemia;Recurrent Adult Acute Myeloid Leukemia;Recurrent Childhood Acute Lymphoblastic Leukemia;Recurrent Childhood Acute Myeloid Leukemia;Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;Refractory Acute Lymphoblastic Leukemia;Refractory Acute Myeloid Leukemia
- United States
- 2014-08-18
Recruiting
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
- Advanced Malignant Solid Neoplasm;Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;Childhood Langerhans Cell Histiocytosis;Histiocytic Sarcoma;Juvenile Xanthogranuloma;Malignant Glioma;Recurrent Central Nervous System Neoplasm;Recurrent Childhood Ependymoma;Recurrent Childhood Malignant Germ Cell Tumor;Recurrent Childhood Medulloblastoma;Recurrent Childhood Non-Hodgkin Lymphoma;Recurrent Childhood Rhabdomyosarcoma;Recurrent Childhood Soft Tissue Sarcoma;Recurrent Ewing Sarcoma;Recurrent Glioma;Recurrent Hepatoblastoma;Recurrent Langerhans Cell Histiocytosis;Recurrent Malignant Solid Neoplasm;Recurrent Neuroblastoma;Recurrent Osteosarcoma;Recurrent Peripheral Primitive Neuroectodermal Tumor;Recurrent Rhabdoid Tumor;Refractory Central Nervous System Neoplasm;Refractory Childhood Malignant Germ Cell Tumor;Refractory Ewing Sarcoma;Refractory Glioma;Refractory Hepatoblastoma;Refractory Langerhans Cell Histiocytosis;Refractory Malignant Solid Neoplasm;Refractory Medulloblastoma;Refractory Neuroblastoma;Refractory Non-Hodgkin Lymphoma;Refractory Osteosarcoma;Refractory Peripheral Primitive Neuroectodermal Tumor;Refractory Rhabdoid Tumor;Refractory Rhabdomyosarcoma;Rhabdoid Tumor;Stage III Osteosarcoma AJCC v7;Stage III Soft Tissue Sarcoma AJCC v7;Stage IV Osteosarcoma AJCC v7;Stage IV Soft Tissue Sarcoma AJCC v7;Stage IVA Osteosarcoma AJCC v7;Stage IVB Osteosarcoma AJCC v7;Wilms Tumor
- Puerto Rico, United States
- 2017-05-15
Recruiting
- Lenalidomide and Blinatumomab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
- CD19 Positive;Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;Recurrent Burkitt Lymphoma;Recurrent Diffuse Large B-Cell Lymphoma;Recurrent Grade 1 Follicular Lymphoma;Recurrent Grade 2 Follicular Lymphoma;Recurrent Grade 3 Follicular Lymphoma;Recurrent Mantle Cell Lymphoma;Recurrent Marginal Zone Lymphoma;Recurrent Mediastinal Lymphoma;Recurrent Non-Hodgkin Lymphoma;Recurrent Small Lymphocytic Lymphoma;Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;Refractory Burkitt Lymphoma;Refractory Diffuse Large B-Cell Lymphoma;Refractory Follicular Lymphoma;Refractory Mantle Cell Lymphoma;Refractory Marginal Zone Lymphoma;Refractory Mediastinal Lymphoma;Refractory Non-Hodgkin Lymphoma;Refractory Small Lymphocytic Lymphoma
- United States
- 2015-10-05
Recruiting
- A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
- Adult Acute Lymphoblastic Leukemia in Remission;Adult Acute Myeloid Leukemia in Remission;Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;Adult Acute Myeloid Leukemia With Del(5q);Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);Adult Nasal Type Extranodal NK/T-cell Lymphoma;Aplastic Anemia;Childhood Acute Lymphoblastic Leukemia in Remission;Childhood Acute Myeloid Leukemia in Remission;Childhood Myelodysplastic Syndromes;Chronic Eosinophilic Leukemia;Chronic Myelomonocytic Leukemia;Chronic Neutrophilic Leukemia;Essential Thrombocythemia;Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;Juvenile Myelomonocytic Leukemia;Mastocytosis;Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;Nodal Marginal Zone B-cell Lymphoma;Polycythemia Vera;Previously Treated Myelodysplastic Syndromes;Primary Myelofibrosis;Recurrent Adult Acute Lymphoblastic Leukemia;Recurrent Adult Acute Myeloid Leukemia;Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;Recurrent Adult Grade III Lymphomatoid Granulomatosis;Recurrent Adult Hodgkin Lymphoma;Recurrent Childhood Acute Lymphoblastic Leukemia;Recurrent Childhood Acute Myeloid Leukemia;Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;Recurrent Grade 1 Follicular Lymphoma;Recurrent Grade 2 Follicular Lymphoma;Recurrent Marginal Zone Lymphoma;Recurrent Mycosis Fungoides/Sezary Syndrome;Recurrent Small Lymphocytic Lymphoma;Recurrent/Refractory Childhood Hodgkin Lymphoma;Refractory Anemia;Refractory Anemia With Ringed Sideroblasts;Refractory Hairy Cell Leukemia;Refractory Multiple Myeloma;Secondary Myelodysplastic Syndromes;Splenic Marginal Zone Lymphoma;T-cell Large Granular Lymphocyte Leukemia;Waldenström Macroglobulinemia;Adult Acute Lymphoblastic Leukemia in Remission;Adult Acute Myeloid Leukemia in Remission;Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;Adult Acute Myeloid Leukemia With Del(5q);Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);Adult Nasal Type Extranodal NK/T-cell Lymphoma;Aplastic Anemia;Childhood Acute Lymphoblastic Leukemia in Remission;Childhood Acute Myeloid Leukemia in Remission;Childhood Myelodysplastic Syndromes;Chronic Eosinophilic Leukemia;Chronic Myelomonocytic Leukemia;Chronic Neutrophilic Leukemia;Essential Thrombocythemia;Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;Juvenile Myelomonocytic Leukemia;Mastocytosis;Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;Nodal Marginal Zone B-cell Lymphoma;Polycythemia Vera;Previously Treated Myelodysplastic Syndromes;Primary Myelofibrosis;Recurrent Adult Acute Lymphoblastic Leukemia;Recurrent Adult Acute Myeloid Leukemia;Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;Recurrent Adult Grade III Lymphomatoid Granulomatosis;Recurrent Adult Hodgkin Lymphoma;Recurrent Childhood Acute Lymphoblastic Leukemia;Recurrent Childhood Acute Myeloid Leukemia;Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;Recurrent Grade 1 Follicular Lymphoma;Recurrent Grade 2 Follicular Lymphoma;Recurrent Marginal Zone Lymphoma;Recurrent Mycosis Fungoides/Sezary Syndrome;Recurrent Small Lymphocytic Lymphoma;Recurrent/Refractory Childhood Hodgkin Lymphoma;Refractory Anemia;Refractory Anemia With Ringed Sideroblasts;Refractory Hairy Cell Leukemia;Refractory Multiple Myeloma;Secondary Myelodysplastic Syndromes;Splenic Marginal Zone Lymphoma;T-cell Large Granular Lymphocyte Leukemia;Waldenström Macroglobulinemia;Adult Acute Lymphoblastic Leukemia in Remission;Adult Acute Myeloid Leukemia in Remission;Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;Adult Acute Myeloid Leukemia With Del(5q);Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);Adult Nasal Type Extranodal NK/T-cell Lymphoma;Aplastic Anemia;Childhood Acute Lymphoblastic Leukemia in Remission;Childhood Acute Myeloid Leukemia in Remission;Childhood Myelodysplastic Syndromes;Chronic Eosinophilic Leukemia;Chronic Myelomonocytic Leukemia;Chronic Neutrophilic Leukemia;Essential Thrombocythemia;Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;Juvenile Myelomonocytic Leukemia;Mastocytosis;Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;Nodal Marginal Zone B-cell Lymphoma;Polycythemia Vera;Previously Treated Myelodysplastic Syndromes;Primary Myelofibrosis;Recurrent Adult Acute Lymphoblastic Leukemia;Recurrent Adult Acute Myeloid Leukemia;Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;Recurrent Adult Grade III Lymphomatoid Granulomatosis;Recurrent Adult Hodgkin Lymphoma;Recurrent Childhood Acute Lymphoblastic Leukemia;Recurrent Childhood Acute Myeloid Leukemia;Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;Recurrent Grade 1 Follicular Lymphoma;Recurrent Grade 2 Follicular Lymphoma;Recurrent Marginal Zone Lymphoma;Recurrent Mycosis Fungoides/Sezary Syndrome;Recurrent Small Lymphocytic Lymphoma;Recurrent/Refractory Childhood Hodgkin Lymphoma;Refractory Anemia;Refractory Anemia With Ringed Sideroblasts;Refractory Hairy Cell Leukemia;Refractory Multiple Myeloma;Secondary Myelodysplastic Syndromes;Splenic Marginal Zone Lymphoma;T-cell Large Granular Lymphocyte Leukemia;Waldenström Macroglobulinemia;Adult Acute Lymphoblastic Leukemia in Remission;Adult Acute Myeloid Leukemia in Remission;Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;Adult Acute Myeloid Leukemia With Del(5q);Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);Adult Nasal Type Extranodal NK/T-cell Lymphoma;Aplastic Anemia;Childhood Acute Lymphoblastic Leukemia in Remission;Childhood Acute Myeloid Leukemia in Remission;Childhood Myelodysplastic Syndromes;Chronic Eosinophilic Leukemia;Chronic Myelomonocytic Leukemia;Chronic Neutrophilic Leukemia;Essential Thrombocythemia;Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;Juvenile Myelomonocytic Leukemia;Mastocytosis;Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;Nodal Marginal Zone B-cell Lymphoma;Polycythemia Vera;Previously Treated Myelodysplastic Syndromes;Primary Myelofibrosis;Recurrent Adult Acute Lymphoblastic Leukemia;Recurrent Adult Acute Myeloid Leukemia;Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;Recurrent Adult Grade III Lymphomatoid Granulomatosis;Recurrent Adult Hodgkin Lymphoma;Recurrent Childhood Acute Lymphoblastic Leukemia;Recurrent Childhood Acute Myeloid Leukemia;Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;Recurrent Grade 1 Follicular Lymphoma;Recurrent Grade 2 Follicular Lymphoma;Recurrent Marginal Zone Lymphoma;Recurrent Mycosis Fungoides/Sezary Syndrome;Recurrent Small Lymphocytic Lymphoma;Recurrent/Refractory Childhood Hodgkin Lymphoma;Refractory Anemia;Refractory Anemia With Ringed Sideroblasts;Refractory Hairy Cell Leukemia;Refractory Multiple Myeloma;Secondary Myelodysplastic Syndromes;Splenic Marginal Zone Lymphoma;T-cell Large Granular Lymphocyte Leukemia;Waldenström Macroglobulinemia
- United States
- 2011-06-27
